Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps

April 24, 2014 Xeris Pharmaceuticals, Inc., a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today the dosing of the first subject in a Phase 2 clinical study of the company’s stable liquid glucagon in an Insulet Corporation OmniPod® infusion pump in patients with type 1 diabetes under a new US Investigational New Drug (IND) …